The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

neucel.com

Neucel Specialty Cellulose has not claimed their Profile.

Want to better differentiate Neucel Specialty Cellulose between your competitors? Show buyers how.

Cognate BioServices company logo

Why does Neucel Specialty Cellulose win vs. Cognate BioServices?

Show Neucel Specialty Cellulose's primary competitive advantage

Show Neucel Specialty Cellulose's competitive differentiation

Neucel Specialty Cellulose's alternatives and competitors

See how Neucel Specialty Cellulose compares to similar products. Neucel Specialty Cellulose's top competitors include Cognate BioServices, MetaBiologics, and HumanZyme.

Cognate BioServices provides a range of commercialization services to regenerative medicine, cellular immunotherapy, and advanced cell therapy companies.On February 17t…

Neucel Specialty Cellulose vs. Cognate BioServices

View more in-depth data on:

  • Competitors
  • Products
  • Customer References and more
  • MetaBiologics manufactures toxins used in healthcare research and in anti-biological weapons research.

    Neucel Specialty Cellulose vs. MetaBiologics

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • HumanZyme is engaged in the production of large quantities of highly active, pure and authentic human proteins in human cells.

    Neucel Specialty Cellulose vs. HumanZyme

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Fusion Antibodies uses technology to rapidly produce fusion proteins from genes and uses these products as antigens for the production and purification of antibodies.

    Neucel Specialty Cellulose vs. Fusion Antibodies

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Roka Bioscience is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the Food Safety Industry. The Atlas System represents a ne…

    Neucel Specialty Cellulose vs. Roka Bioscience

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • This company, formerly known as Sceptor, is a global diagnostics, biological collection and detection systems company dedicated to improving the quality of life and wor…

    Neucel Specialty Cellulose vs. Evogen

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to …

    Neucel Specialty Cellulose vs. NeoClone

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Cogentus Pharmaceuticals is a privately held specialty pharmaceutical company founded in 2006. Cogentus is committed to becoming a premier developer of innovative, fixe…

    Neucel Specialty Cellulose vs. Cogentus Pharmaceuticals

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Transgenomic (NASDAQ:TBIO) is a global biotechnology company that advances personalized medicine in oncology and inherited diseases via its products and services for au…

    Neucel Specialty Cellulose vs. Transgenomic

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Charles River Laboratories (NYSE: CRL) provides products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic inst…

    Neucel Specialty Cellulose vs. Charles River Laboratories

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Biomm offers a recombinant human protein production platform.

    Neucel Specialty Cellulose vs. Biomm

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • The company's core business is and remains the development and production of Active Pharmaceutical Ingredient and parenteral formulations in the the form of solution an…

    Neucel Specialty Cellulose vs. Neon

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more
  • Microarray was formed in July 2000, as a joint venture between Manchester Metropolitan University (MMU) and the The University of Manchester. Microarray also offers co…

    Neucel Specialty Cellulose vs. Microarray

    View more in-depth data on:

    • Competitors
    • Products
    • Customer References and more

Work for Neucel Specialty Cellulose?

Brief our analysts.

Get in front of tech buyers.

100% free.

No pay-to-play nonsense.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

A
Adimab

Adimab is engaged in the discovery, maturation and production of therapeutic human antibodies. Per the company, Adimab integrates all aspects of antibody discovery and sophisticated screening methods, and therefore can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. The company states that their proprietary library design and presentation technology allows Adimab to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.

B
Biomm

Biomm offers a recombinant human protein production platform.

E
EMTech

EMTech, a spin-off of BiOva, LLC, is researching, developing, and manufacturing technologies for the metabolic enhancement of the enzymes and bacteria used in the fermentation industry. The company's current products and ongoing research projects show applications that enhance productivity in the ethanol, pharmaceutical, beer, wine, and dairy industries.

N
Novacta Biosystems

Aiming to leverage the knowledge of GSK's Biotransformation and Natural Products scientific team, Novacta Biosystems Ltd was founded in 2003. In the following 5 years, Novacta successfully adopted a dual business model, whereby it developed a biocatalysis and microbial pathway engineering service business, that supported its efforts to build an infectious disease therapeutic pipeline.

M
Matrix Sensors

Matrix Sensors aims to democratize air quality sensors for a cleaner, healthier, and safer world.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.